医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Meiji Seika Pharma

Meiji Seika Pharma: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufacturing Facility in India to Enhance its CMO Business

Meiji Seika Pharma: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufacturing Facility in India to Enhance its CMO Business

その他ヘルスヘルスケア製薬　 TimeLine: Adcock Ingram Pharma Private Limited Completes Construction of a New Manufacturing Facility in India to Enhance its CMO Business Meiji Seika Pharma

2023年05月31日

Meiji Seika Pharma: First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada

Meiji Seika Pharma: First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: a Selective PDE4 Inhibitor First Patient Dosed in Phase II Study of ME3183 in Patients with Plaque Psoriasis in the United States and Canada Meiji Seika Pharma

2022年04月07日

Meiji Seika Pharma: Adcock Ingram Ltd. in India to Build a New Manufacturing Facility to Enhance Its CMO Business

Meiji Seika Pharma: Adcock Ingram Ltd. in India to Build a New Manufacturing Facility to Enhance Its CMO Business

ヘルスケアヘルス一般製薬　 TimeLine: Adcock Ingram in India to Build a New Manufacturing Facility to Enhance Its CMO Business Meiji Seika Pharma

2021年11月08日

CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: a Proposed Ustekinumab Biosimilar CORRECTING and REPLACING Meiji Seika Pharma Phase I Clinical Trial of DMB-3115 Promising Results

2021年05月21日

Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: a Proposed Ustekinumab Biosimilar and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis Meiji Seika Pharma Phase I Clinical Trial of DMB-3115 Promising Results

2021年05月21日